AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06563739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-exposed group
Description: Traditional rehabilitation assessment and training guidance
Study NCT06564428 — intervention group
Intervention type: GENETIC
Intervention: Suspective gene mutations and family history
Description: To observe if the patients with suspective gene mutations or family history take higher risk of suffering from ovarian cancer.
Study NCT06639126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild thyme extract
Description: All patients will be randomized (1:1) to receive the active thyme extract (600 mg/capsule/day or 600 mg/capsule/day of microcrystalline cellulose) in the form of capsules, administered orally and daily for 2 months
Study NCT06639126 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 600 mg/day microcrystalline cellulose
Study NCT06294990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Two years treatment with testosterone
Study NCT06294990 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two years treatment with placebo
Study NCT06639399 — intervention group
Intervention type: OTHER
Intervention: Acupuncture
Description: Patients received acupuncture treatment at the lumbosacral region, all acupoints belong to the bladder meridian, including Shenshu (BL23), Pangguangshu (BL28), Ciliao (BL32), Huiyang (BL35), and Zhibian (BL54) selected bilaterally. Electroacupuncture (EA) was applied to the BL32 and BL54 acupoints at a frequency of 2/100Hz. Each treatment lasting for 30 minutes. Patients received five acupuncture treatments per week for two consecutive weeks
Study NCT06639399 — intervention group
Intervention type: OTHER
Intervention: Acupuncture
Description: Patients received acupuncture treatment using a comprehensive acupoint combination scheme. In addition to the acupoints used in Group A, the following acupoints were added: Qihai (RN6), Guanyuan (RN4), Zhongji (RN3), Shuidao (ST28), Yinglingquan (S9), and Sanyinjiao (SP6). The acupuncture and EA procedure for the lumbosacral acupoints was the same as in Group A. After 30 minutes of treatment, abdominal and lower limb acupoints were selected for an additional 30 minutes treatment.Each treatment lasting for 60 minutes.Patients received five acupuncture treatments per week for two consecutive weeks
Study NCT06637137 — intervention group
Intervention type: DRUG
Intervention: Iron
Description: Patients who present a state of hypoferritinemia or a state of reduced transferrin saturation will undergo administration of i.v iron at least 2 weeks before scheduled cardiac surgery, plus acid folic and B vitamin co-administration.
Study NCT06565286 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inner preputial graft versus transverse preputial island flap in two-stage repair of proximal penile hypospadias
Description: compare outcomes of inner preputial graft versus transverse preputial island flap when used to substitute the urethral plate in two-stage repair of primary proximal penile hypospadias .
Study NCT06467435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kamuvudine-9
Description: 96 mg tablets taken once
Study NCT05964699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive periodontal therapy with use of Emdogain
Description: Scaling of root with assisted use of the Videoscope and regrowth of attachment by the use of Emdogain.
Study NCT05964699 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Minimally invasive periodontal therapy without the use of Emdogain
Description: Scaling of root with assisted use of the Videoscope.
Study NCT04998630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Description: Treatment Location: Painful Area Treatment intensity: 2000 pulses, low energy (0.08\~0.28 mJ/m2) the degree to which the subject can tolerate
Study NCT06529627 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long Gn-RH agonist protocol - Intracytoplasmic Sperm Injection
Description: pituitary downregulation with GnRH agonist - ovarian stimulation with exogenous gonadotropin - hCG adminstration as trigger of oocyte maturation Oocyte retriveal via transvaginal ultrasound guided aspiration embryo transfer progesterone as luteal phase support
Study NCT05603676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent hypoxia-hyperoxia conditioning
Description: The IHHC protocol consist of 6 bouts of 6 min breathing hypoxia (FiO2 = 11.5%) following by 3 min breathing hyperoxia (FiO2 = 31.5%) (Figure 2). The total duration of a session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with hypo and hyperoxic gas mixture. Participants will be instructed to relax and breath normally throughout the session.
Study NCT05603676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia-hyperoxia conditioning
Description: The IHHC protocol consist of 6 bouts of 6 min breathing hypoxia (FiO2 = 11.5%) following by 3 min breathing hyperoxia (FiO2 = 31.5%) (Figure 2). The total duration of a session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with hypo and hyperoxic gas mixture. Participants will be instructed to relax and breath normally throughout the session.
Study NCT05603676 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo intervention
Description: Placebo intervention will be like the IHHC protocol but with mixing chambers full of ambient air. The total duration of a placebo session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with ambient air. Participants will be instructed to relax and breath normally throughout the session.
Study NCT05603676 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Placebo intervention will be like the IHHC protocol but with mixing chambers full of ambient air. The total duration of a placebo session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with ambient air. Participants will be instructed to relax and breath normally throughout the session.
Study NCT06052553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TopSpin360
Description: Helmet training device used to train head to stay stable during jarring impacts through dynamic and multi-planar neck strengthening.
Study NCT06275867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free high-quality care
Description: Participants are able to take their child to receive free consultations and treatment in a network of contracted private healthcare providers.
Study NCT06275867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Close distance
Description: The network of contracted providers is located close to where participants live.
Study NCT06275867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Far distance
Description: The network of contracted providers is located far to where participants live.
Study NCT05516875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JM-010
Description: JM-010
Study NCT05200481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 MG
Description: Patients will receive brigatinib orally at a dose of 90 mg QD for a 7 days lead-in period followed by 180 mg QD continuously, with or without food, in 28-day cycles until progression. Dose reductions are possible.
Study NCT05200481 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Brigatinib 180 MG
Description: Patients will receive brigatinib orally at a dose of 90 mg QD for a 7 days lead-in period followed by 180 mg QD continuously, with or without food, in 28-day cycles until progression. Dose reductions are possible.
Study NCT05200481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
Study NCT05200481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
Study NCT06040827 — intervention group
Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: The nature, severity, and frequency of safety risks (Adverse Events) in subjects with the Canary canturioTM te will be compared to those subjects with the legally marketed Zimmer Persona® Personalized Knee System with 14 mm x +30 mm stem extension within 5 years post-TKA.
Study NCT06352463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Denken + Doen = Durven
Description: DDD is an evidence based cognitive behavioural therapy (CBT)-treatment protocol for children with anxiety. This research will use the modular version of DDD, which means that the therapist will decide which modules she will use based on the specific symptoms and needs of the child. DDD consists of four parts. First, there will be psycho education in which the child learns about how anxiety can arise, when anxiety is normal, and how thoughts, emotions, and behaviour are linked. Second, the child will learn coping strategies for dealing with anxiety. Third, there will be cognitive restructuring by which that the child will learn skills to deal with anxious and negative thoughts, through challenging and experimenting. Finally, there will be exposure. In the exposure sessions, the child will face their fears step by step.
Study NCT06352463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Parenting for Anxious Childhood Emotions
Description: Parents will follow the SPACE program. SPACE is a theory driven, evidence-based treatment program of 12 sessions. In a structured way, parents are trained to change their own behaviour as a reaction to the symptoms of their child. First, they are trained to recognise family accommodation and slowly reduce this. Second, this program focuses on the increase in supportive reactions from parents. They are taught to accept the child's feelings, fears, and problems and to trust in the ability of the child to cope with and tolerate anxiety-related problems. These two goals are attained via a sequence of steps in the SPACE manual. Furthermore, SPACE includes additional modules that can be implemented if needed. These provide tools for conquering communal challenges that can arise during the treatment process, including dealing with extremely disruptive behaviour of children and improving parental collaboration.
Study NCT05620940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivitrol Injectable Product
Description: Naltrexone Long-Acting Injection
Study NCT05620940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVL3004
Description: Naltrexone Long-Acting Injection
Study NCT05620940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVL4002
Description: Naltrexone Long-Acting Injection
Study NCT06134401 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: nebulised
Study NCT06134401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: saline
Description: nebulised
Study NCT05897775 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Deep brain stimulation
Description: Thalamic coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS (T-DBS) that uses continuous high amplitude, high frequency stimulation.~Each participant will receive both the new intervention and the standard of care intervention, each for a week.
Study NCT05897775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Thalamic coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS (T-DBS) that uses continuous high amplitude, high frequency stimulation.~Each participant will receive both the new intervention and the standard of care intervention, each for a week.
Study NCT06445439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing rate of 80 bpm
Description: Pacing rate of 80 bpm
Study NCT06445439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing rate of 60 bpm
Description: Pacing rate of 60 bpm
Study NCT05280652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional and culinary intervention
Description: Participants will attend 6 two-hours nutritional-culinary workshops between May 2022 and February 2023. All of the workshops will be held in a kitchen, and will be given in groups of 2 dyads or parents according to the intervention group. In addition, during the intervention families will be given access to a web page with nutrition and culinary education materials (infographics, videos).
Study NCT05280652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional intervention
Description: Participants will attend 6 1-hour nutritional workshops between May 2022 and February 2023. The workshops will be held in person, and will be given in groups of 10-12 families. In addition, during the intervention families will be given access to a web page with nutrition education materials (infographics, videos).
Study NCT06639867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-based home physiotherapy
Description: VR-based home physiotherapy
Study NCT06639867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy care
Description: Standard physiotherapy care as prescribed by the treating physiotherapist
Study NCT06639191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-AKIR001
Description: Patient cohorts of a minimum of three and a maximum of 12 evaluable participants will be opened according to the decision tree defined in the protocol and will be consecutively completed. When one cohort has been completed and fully evaluated, the next cohort will be opened after all participants in the previous cohort have received at least one dose of the IMP without dose-limiting toxicities during a follow-up period of at least six weeks.~The \[177Lu\]Lu-AKIR001 protein mass dose and activity are predefined for each cohort, and could be adjusted according to the results of previous cohort(s) to ensure the safety of participants. The initial design of the trial encompasses five cohorts to escalate both \[177Lu\]Lu-AKIR001 pmd, from 50 mg to 100 mg, and activity, from 0.75 to 3.0 GBq.
Study NCT06640179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: Standard Care Intervention will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
Study NCT06640179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: Standard Care Intervention will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
Study NCT06640179 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Contacts
Description: Participants will receive brief conducts (\<10 minutes) remotely (telephone or video platform) with the research staff at weeks 6, 12, and 18.
Study NCT06640179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Sessions
Description: Participants will be provided weekly individual behavioral sessions during the 6-month intervention to assist in supporting recommended changes in energy intake (diet) and physical activity.
Study NCT06640179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: An energy balanced diet to meet energy needs that will allow for weight maintenance will be prescribed. This will be estimated using the Mifflin-St. Joer equation to estimate resting metabolic rate and for most participants we anticipate using a physical activity correction of 1.3 to account for energy needs for physical activity. This will provide the initial estimate of energy intake needs to maintain weight stability; however, the prescribed level of energy intake will be adjusted at 4-week intervals across the intervention based on the observed changes in weight, eating behaviors, and physical activity patterns in an effort to prevent excessive weight gain. Within the context of this level of energy intake, we will prescribe a diet that is consistent with the dietary recommendations of the National Kidney Foundation.
Study NCT05081765 — intervention group
Intervention type: DRUG
Intervention: Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)
Description: correlation between C through and taken drug
Study NCT05081765 — intervention group
Intervention type: DEVICE
Intervention: Lynparza
Description: correlation between C through and taken drug
Study NCT06640179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical activity will be recommended in the form of aerobic types of activity such as brisk walking and will progress in 4-week intervals from an initial amount of 50 minutes per week to 150 minutes per week across the initial 6 months of the intervention. Moderate intensity will be prescribed, and will be anchored using RPE (rating of perceived exertion) to allow intensity to be self-regulated according to the participant's capacity. Physical activity will be prescribed in the form of walking; however, the participant will be permitted to engage in other forms of physical activity that meet the recommended dose and intensity.
Study NCT06638008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perineural injection
Description: perineural intervention of placental growth factor in one group and PRP in other group
Study NCT06639282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siponimod
Description: Siponimod (formerly known as BAF312 and completed trial NCT #01665144) has been FDA approved since 2019 (IND #076122) for the treatment of multiple sclerosis. Siponimod is an immunomodulator that prevents the egression of T lymphocytes from peripheral lymphoid organs.
Study NCT06639282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo that resembles siponimod will be given once daily to participants randomly assigned into the placebo arm.
Study NCT06642649 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia (control group)
Description: Only General Anestesia
Study NCT06642649 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia + Spinal anesthesia combined
Description: General anesthesia + spinal anesthesia with local anesthetic and morfine
Study NCT06642649 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia + Spinal anesthesia combined
Description: General anesthesia + spinal anesthesia with local anesthetic, morfine and fentanyl
Study NCT06641388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ebronucimab
Description: Ebronucimab subcutaneous injection
Study NCT06644807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor Cortex Stimulation
Description: Motor Cortex Stimulation (MCS) is a neuromodulation technique that involves the surgical implantation of electrodes over the motor cortex, typically targeting the precentral gyrus, to deliver electrical stimulation. The procedure involves placing an electrode grid or strip on the dura mater overlying the motor cortex, which is identified via neuroimaging techniques such as functional MRI or neuronavigation. Once implanted, the electrodes are connected to an implanted pulse generator (IPG), which delivers adjustable electrical impulses.
Study NCT06644807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: Spinal Cord Stimulation (SCS) is a neuromodulation that involves the implantation of a device that delivers electrical impulses to the spinal cord through an electrode placed in the epidural space. The stimulation alters pain signals before they reach the brain, effectively masking or reducing the sensation of pain.
Study NCT06644807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: Peripheral Nerve Stimulation (PNS) is a neuromodulation technique used to treat chronic pain. The procedure starts with a preoperative assessment, including imaging to identify the target peripheral nerve. Under local anesthesia, a thin, insulated electrode is implanted near the nerve, usually with the help of fluoroscopic or ultrasound guidance for precision.
Study NCT06644807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion Stimulation
Description: Dorsal Root Ganglion Stimulation (DRGS) is a targeted neuromodulation technique for managing chronic pain. The procedure begins with a thorough preoperative assessment, including imaging to locate the specific dorsal root ganglion (DRG) associated with the pain. Under local anesthesia, a small electrode is implanted near the DRG. This is done through a minimally invasive procedure, often guided by fluoroscopy or CT imaging to ensure precise placement.